FOLD Amicus Therapeutics, Inc.

7.37
+0  (3%)
Previous Close 7.18
Open 7.25
Price To book 2.84
Market Cap 1.44B
Shares 194,824,000
Volume 1,363,031
Short Ratio 10.04
Av. Daily Volume 2,870,040

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Additional trials required following feedback from FDA. Enrollment to commence 2017 with data due in 2019.
Migalastat HCl monotherapy (012)
Fabry Disease
"Phase 3 enrollment completed April 3, 2017 with top-line data due 3Q 2017. "
SD-101
Epidermolysis Bullosa (EB)
Phase 1/2 additional data released February 15, 2017. Further data due 2Q and 3Q 2017.
ATB200
Pompe Disease

Latest News

  1. Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
  2. Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
  3. Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics
  4. Are These 2 Biotechs Diamonds in the Rough?
  5. Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy
  6. Harry Boxer’s six biotechnology stocks to watch
  7. Four biotech stocks surging on optimism about drug trials, product launches
  8. Biotechs Breaking Out On Drug Development News
  9. Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA
  10. Dow Soars Above 21,000 for the First Time in History: Today's Reports on Clean Energy Fuels and Amicus Therapeutics
  11. Amicus Therapeutics to Present at Upcoming Investor Conferences
  12. Edited Transcript of FOLD earnings conference call or presentation 1-Mar-17 1:30pm GMT
  13. Trump's latest comments are 'constructive' for drug industry: Amicus Therapeutics CEO
  14. Amicus Therapeutics CEO: Trump constructive for our indus...
  15. Why Amicus Therapeutics, Inc. Jumped Higher Today
  16. 4 Biopharma Stocks Moving the Market on Wednesday
  17. Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
  18. Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates
  19. Amicus Therapeutics Launches Galafold in UK
  20. Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in the United Kingdom

SEC Filings

  1. 8-K - Current report 17732320
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 17685717
  3. 8-K - Current report 17673908
  4. 10-K/A (Amend) - Annual report (Section 13 and 15(d), not S-K Item 405) 17665283
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17654246
  6. 8-K - Current report 17651641
  7. 8-K - Current report 17616446
  8. 8-K - Current report 17615715
  9. 8-K - Current report 17612930
  10. 8-K - Current report 17611735